ArticleAnais brasileiros de dermatologia2019
Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology.
Article in Anais brasileiros de dermatologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Single Center, Open-label, Non-randomized Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion and the Safety and Perceived Efficacy of a Lip Moisturizer in Adults With Atopic Dermatitis Presenting Dermatological Lesion.
Single Center, Open-label, Non-randomized Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion During and After 21 ± 2 Days of Use in Adults With Atopic Dermatitis.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Global Guidelines in Dermatology Mapping Project (GUIDEMAP), a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)?The British journal of dermatology · 2022Pooled it
- A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study withFrontiers in immunology · 2025Trial
- Burden, Treatment Patterns and Real-World Barriers to Prescribing Advanced Treatments in Adults with Atopic Dermatitis in Brazil and Colombia.Dermatology and therapy · 2026Article
- Article
- International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- A systematic review of guidelines for the management of atopic dermatitis in children.The World Allergy Organization journal · 2024Review
- Review
- Atopic Dermatitis in Latin America: Considerations on Epidemiology, Clinical and Laboratory Features, Ethnic/Racial Variations, and Therapeutic Management.Journal of clinical medicine · 2023Review
- Healthcare Disparities in Atopic Dermatitis in Latin America: A Narrative Review.Dermatology and therapy · 2023Review
- Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis.Einstein (Sao Paulo, Brazil) · 2021Article
- Different Approaches to Atopic Dermatitis by Allergists, Dermatologists, and Pediatricians.Dermatology research and practice · 2021Article
- Atopic dermatitis: Tofacitinib, an option for refractory disease.Clinical case reports · 2020Article
- Mesenchymal Stem Cells and Atopic Dermatitis: A Review.Frontiers in cell and developmental biology · 2020Review
- Methotrexate for refractory adult atopic dermatitis leads to alterations in cutaneous IL-31 and IL-31RA expression.Anais brasileiros de dermatologiaArticle
- Consensus on the therapeutic management of atopic dermatitis ‒ Brazilian Society of Dermatology: an update on phototherapy and systemic therapy using e-Delphi technique.Anais brasileiros de dermatologiaArticle
- Alopecia areata-like and psoriasis after dupilumab use for atopic dermatitis.Anais brasileiros de dermatologiaArticle
- Use of cyclosporine in children and adolescents with moderate to severe atopic dermatitis: clinical experience in a tertiary Hospital.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtopic dermatitis is a highly prevalent inflammatory and pruritic dermatosis with a multifactorial etiology, which includes skin barrier defects, immune dysfunction, and microbiome alterations. Atopic dermatitis is mediated by genetic, environmental, and psychological factors and requires therapeutic management that covers all the aspects of its complex pathogenesis.
objectivesThe aim of this article is to present the experience, opinions, and recommendations of Brazilian dermatology experts regarding the therapeutic management of atopic dermatitis.
methodsEighteen experts from 10 university hospitals with experience in atopic dermatitis were appointed by the Brazilian Society of Dermatology to organize a consensus on the therapeutic management of atopic dermatitis. The 18 experts answered an online questionnaire with 14 questions related to the treatment of atopic dermatitis. Afterwards, they analyzed the recent international guidelines on atopic dermatitis of the American Academy of Dermatology, published in 2014, and of the European Academy of Dermatology and Venereology, published in 2018. Consensus was defined as approval by at least 70% of the panel. RESULTS/
conclusionThe experts stated that the therapeutic management of atopic dermatitis is based on skin hydration, topical anti-inflammatory agents, avoidance of triggering factors, and educational programs. Systemic therapy, based on immunosuppressive agents, is only indicated for severe refractory disease and after failure of topical therapy. Early detection and treatment of secondary bacterial and viral infections is mandatory, and hospitalization may be needed to control atopic dermatitis flares. Novel target-oriented drugs such as immunobiologicals are invaluable therapeutic agents for atopic dermatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.